Cargando…
Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis
The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014....
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397058/ https://www.ncbi.nlm.nih.gov/pubmed/34441995 http://dx.doi.org/10.3390/jcm10163701 |
_version_ | 1783744528605249536 |
---|---|
author | Jang, Sun-Joo Yeo, Ilhwan Jonas, Chanel Goyal, Parag Cheung, Jim W. Feldman, Dmitriy N. McCullough, S. Andrew Krishnan, Udhay Narotsky, David L. Singh, Harsimran S. Minutello, Robert M. Bergman, Geoffrey Wong, S. Chiu Kim, Luke K. |
author_facet | Jang, Sun-Joo Yeo, Ilhwan Jonas, Chanel Goyal, Parag Cheung, Jim W. Feldman, Dmitriy N. McCullough, S. Andrew Krishnan, Udhay Narotsky, David L. Singh, Harsimran S. Minutello, Robert M. Bergman, Geoffrey Wong, S. Chiu Kim, Luke K. |
author_sort | Jang, Sun-Joo |
collection | PubMed |
description | The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy. |
format | Online Article Text |
id | pubmed-8397058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83970582021-08-28 Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis Jang, Sun-Joo Yeo, Ilhwan Jonas, Chanel Goyal, Parag Cheung, Jim W. Feldman, Dmitriy N. McCullough, S. Andrew Krishnan, Udhay Narotsky, David L. Singh, Harsimran S. Minutello, Robert M. Bergman, Geoffrey Wong, S. Chiu Kim, Luke K. J Clin Med Article The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy. MDPI 2021-08-20 /pmc/articles/PMC8397058/ /pubmed/34441995 http://dx.doi.org/10.3390/jcm10163701 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jang, Sun-Joo Yeo, Ilhwan Jonas, Chanel Goyal, Parag Cheung, Jim W. Feldman, Dmitriy N. McCullough, S. Andrew Krishnan, Udhay Narotsky, David L. Singh, Harsimran S. Minutello, Robert M. Bergman, Geoffrey Wong, S. Chiu Kim, Luke K. Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis |
title | Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis |
title_full | Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis |
title_fullStr | Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis |
title_full_unstemmed | Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis |
title_short | Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis |
title_sort | thirty-day readmission rates after takotsubo syndrome with or without malignancy: a nationwide readmissions database analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397058/ https://www.ncbi.nlm.nih.gov/pubmed/34441995 http://dx.doi.org/10.3390/jcm10163701 |
work_keys_str_mv | AT jangsunjoo thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT yeoilhwan thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT jonaschanel thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT goyalparag thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT cheungjimw thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT feldmandmitriyn thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT mcculloughsandrew thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT krishnanudhay thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT narotskydavidl thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT singhharsimrans thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT minutellorobertm thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT bergmangeoffrey thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT wongschiu thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis AT kimlukek thirtydayreadmissionratesaftertakotsubosyndromewithorwithoutmalignancyanationwidereadmissionsdatabaseanalysis |